Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Previously Published Works bannerUC San Diego

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.

  • Author(s): Said, Rabih
  • Ye, Yang
  • Falchook, Gerald Steven
  • Janku, Filip
  • Naing, Aung
  • Zinner, Ralph
  • Blumenschein, George R
  • Fu, Siqing
  • Hong, David S
  • Piha-Paul, Sarina Anne
  • Wheler, Jennifer J
  • Kurzrock, Razelle
  • Palmer, Gary A
  • Aldape, Kenneth
  • Hess, Kenneth R
  • Tsimberidou, Apostolia Maria
  • et al.
Abstract

Background

KRAS mutation is common in human cancer. We assessed the clinical factors, including type of KRAS mutation and treatment, of patients with advanced cancer and tumor KRAS mutations and their association with treatment outcomes.

Methods

Patients referred to the Phase I Clinic for treatment who underwent testing for KRAS mutations were analyzed.

Results

Of 1,781 patients, 365 (21%) had a KRAS mutation. The G12D mutation was the most common mutation (29%). PIK3CA mutations were found in 24% and 10% of patients with and without KRAS mutations (p<0.0001). Of 223 patients with a KRAS mutation who were evaluable for response, 56 were treated with a MEK inhibitor-containing therapy and 167 with other therapies. The clinical benefit (partial response and stable disease lasting ≥6 months) rates were 23% and 9%, respectively, for the MEK inhibitor versus other therapies (p=0.005). The median progression-free survival (PFS) was 3.3 and 2.2 months, respectively (p=0.09). The respective median overall survival was 8.4 and 7.0 months (p=0.38). Of 66 patients with a KRAS mutation and additional alterations, higher rates of clinical benefit (p=0.04), PFS (p=0.045), and overall survival (p=0.02) were noted in patients treated with MEK inhibitor-containing therapy (n=9) compared to those treated with targeted therapy matched to the additional alterations (n=24) or other therapy (n=33).

Conclusions

MEK inhibitors in patients with KRAS-mutated advanced cancer were associated with higher clinical benefit rates compared to other therapies. Therapeutic strategies that include MEK inhibitors or novel agents combined with other targeted therapies or chemotherapy need further investigation.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View